SCHEMBL17345479

SCHEMBL17345479

O=C(CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O)OCc1ccc(C(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.49
▸ STAT3 P40763 3/20 0.49
▸ MAPT P10636 6/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CDC25B P30305 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PSMD14 O00487 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ TTR P02766 1/20 0.41
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ RXRG P48443 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18691835 0.92 ALDH1A1 (0.55) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL29448087 0.86 STAT3 (0.48) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL18691815 0.86 STAT3 (0.48) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL17345489 0.86 STAT3 (0.46) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL17345537 0.82 STAT3 (0.55) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL17345527 0.82 STAT3 (0.49) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL17345565 0.82 ALDH1A1 (0.51) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL18691828 0.81 ALDH1A1 (0.59) ALDH1A1STAT3MAPTLMNASMN1; SMN2
SCHEMBL18691819 0.81 STAT3 (0.52) ALDH1A1STAT3MAPTLMNANPC1
SCHEMBL17345568 0.80 STAT3 (0.55) ALDH1A1STAT3MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11267797-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2022-03-08 — — US disclosed
US-20200317630-A1 ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2020-10-08 — — US disclosed
US-10689355-B2 Anticancer agent Kyoto Pharmaceuticals Industries, Ltd. (JP) 2020-06-23 — — US disclosed
US-20190322636-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-10-24 — — US disclosed
US-10377730-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2019-08-13 — — US disclosed
US-10005752-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-06-26 — — US disclosed
US-10005752-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2018-06-26 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
EP-3153508-A1 NOVEL ANTICANCER AGENT Kyoto Pharmaceutical Industries, Ltd. (JP) 2017-04-12 — — EP disclosed
WO-2015190489-A1 NOVEL ANTICANCER AGENT 京都薬品工業株式会社 2015-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121299-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885
US-20200317630-A1 ANTICANCER AGENT TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-10005752-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-11267797-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-20190322636-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 ALDH1A1 187/4885STAT3 1231/4885MAPT 4391/4885
US-10689355-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885
US-10377730-B2 Anticancer agent TP53, NTPCR, NQO1 ALDH1A1 160/4885STAT3 1303/4885MAPT 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback